Ocular Therapeutix plans wet AMD drug filing for late 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
June 17, 2026 8:45 AM EDTPer May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data
Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements
Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026
SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan
Ocular will... More
